Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Simulations Plus
Its shares trade under the ticker SLP. It has been listed since 18 June 1997. In the fiscal year to 31 August 2025, it reported revenue of $79.2m and a net loss of $64.7m. At that date it held total assets of $131.9m and shareholders' equity of $124.8m.
Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. The company is headquartered in Lancaster, California. The firm offers its products and services through two business segments, which include Simulations Plus, Inc. and Cognigen Corporation. Cognigen Corporation is the subsidiary of the Company. Its pharmaceutical/chemistry software is used by various companies, such as pharmaceutical, biotechnology, agrochemical, and food industry companies and to regulatory agencies for use in the conduct of industry-based research. Its clinical-pharmacology-based consulting services include pharmacokinetic and pharmacodynamics modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 18 Jun 1997
- Employees
- 212
- Website
- simulations-plus.com ↗
- Head office
- 600 PARK OFFICES DRIVE, SUITE 300 #4134, DURHAM, NC, 27713
- Classification
- Services-Computer Integrated Systems Design
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Daniel WeinerNon-Executive Chairman of the Board$210,071
- Mr. Shawn O'ConnorChief Executive Officer$1.7m
- Mr. William FrederickChief Financial Officer, Executive Vice President$1.0m
- Ms. Jill Fiedler-KellyInterim President - Services Solutions$722,102
- Mr. Josh FoheyChief Operating Officer
- Mr. Murry AlperGlobal Head - Medical Communications
- Mr. Steven ChangGlobal Head - Strategic Alliances$656,414
- Dr. Jonathan ChauvinCo-Chief Product and Technology Officer
- Mr. John DibellaChief Revenue Officer$661,624
- Mr. Erik GuffreyCo-Chief Product and Technology Officer
- Ms. Jenna RouseGlobal Head - Clinical Operations
- Ms. Sharlene EvansIndependent Director$187,571
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 32
- Social
- 58
- Governance
- 54
- Women in the workforce
- 48%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Simulations Plus Inc has established itself as a leader in the field of pharmaceutical software and consulting services.
- The company has a strong reputation for providing high-quality and reliable solutions that help improve drug discovery and development processes.
- Simulations Plus Inc has a diverse customer base, including leading pharmaceutical companies, regulatory agencies, and academic institutions.
Weaknesses
- Despite its strong reputation, Simulations Plus Inc faces competition from other software and consulting companies operating in the same industry.
- The company's reliance on a few key customers for a significant portion of its revenue poses a potential risk.
- Simulations Plus Inc may face challenges in adapting to rapidly changing technological advancements in the pharmaceutical industry.
Opportunities
- The increasing demand for innovative software and consulting solutions in drug development provides growth opportunities for Simulations Plus Inc.
- The company can expand its market presence by targeting emerging pharmaceutical markets in regions such as Asia-Pacific and Latin America.
- Collaboration with research institutions and government agencies can open avenues for new projects and partnerships.
Threats
- Simulations Plus Inc may face potential threats from regulatory changes that affect the drug development and approval process.
- The emergence of new competitors with advanced technology and lower pricing can pose a threat to the company's market share.
- Fluctuations in exchange rates and economic instability can impact the company's international operations and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.